Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: The ADAGIO study

Filomena Mazzeo, Lionel Duck, Eric Joosens, Luc Dirix, Christian Focan, Frédéric Forget, Sabina De Geest, Katja Muermans, Marie Anne Van Lierde, Karen Macdonald, Ivo L Abraham, Jacques De Grève

Research output: Contribution to journalArticle

25 Scopus citations


Aim: To determine imatinib nonadherence rates in patients with gastrointestinal tumors (GIST) over 90 days. Patients and Methods: A prospective 90-day observational, open-label, multicenter study was carried out of 28 evaluable GIST patients on imatinib. Nonadherence behavior was measured using a 4-item patient interview. Clinicians, patients, and collaterals rated perceived patient adherence on a 0-100 VAS scale. Results: Nonadherence rates in the 4 weeks prior to baseline and follow-up were 29% (95% CI=26-32) and 24% (95% CI=21-27, p>0.05). Mean VAS ratings of perceived adherence ranged from 952±102 to 973±4.8 (p>0.05 for time and source of rating). Correlations between perceptions of and actual adherence behavior were negative. Conclusion: In this first study on imatinib nonadherence in GIST patients, rates were similar to those observed in patients with chronic myeloid leukemia, higher than clinically expected and exceeding meta-analytic estimates for cancer. Nonadherence rates were consistent across the 90-day period. Nonadherence behavior should be assessed by clinicians.

Original languageEnglish (US)
Pages (from-to)1407-1410
Number of pages4
JournalAnticancer Research
Issue number4
Publication statusPublished - Apr 2011



  • ADAGIO study
  • Adherence
  • Gastrointestinal stromal tumor
  • Imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mazzeo, F., Duck, L., Joosens, E., Dirix, L., Focan, C., Forget, F., ... De Grève, J. (2011). Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: The ADAGIO study. Anticancer Research, 31(4), 1407-1410.